GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » ROA %

BioLine Rx (BioLine Rx) ROA % : -95.11% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. BioLine Rx's annualized Net Income for the quarter that ended in Dec. 2023 was $-55.54 Mil. BioLine Rx's average Total Assets over the quarter that ended in Dec. 2023 was $58.39 Mil. Therefore, BioLine Rx's annualized ROA % for the quarter that ended in Dec. 2023 was -95.11%.

The historical rank and industry rank for BioLine Rx's ROA % or its related term are showing as below:

BLRX' s ROA % Range Over the Past 10 Years
Min: -94.49   Med: -40.73   Max: -31.63
Current: -94.49

During the past 13 years, BioLine Rx's highest ROA % was -31.63%. The lowest was -94.49%. And the median was -40.73%.

BLRX's ROA % is ranked worse than
82.52% of 1556 companies
in the Biotechnology industry
Industry Median: -35.515 vs BLRX: -94.49

BioLine Rx ROA % Historical Data

The historical data trend for BioLine Rx's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx ROA % Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.35 -59.53 -42.05 -31.63 -86.40

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.01 -67.09 -116.29 -114.66 -95.11

Competitive Comparison of BioLine Rx's ROA %

For the Biotechnology subindustry, BioLine Rx's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's ROA % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's ROA % falls into.



BioLine Rx ROA % Calculation

BioLine Rx's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-60.614/( (76.384+63.925)/ 2 )
=-60.614/70.1545
=-86.40 %

BioLine Rx's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-55.536/( (52.855+63.925)/ 2 )
=-55.536/58.39
=-95.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


BioLine Rx  (NAS:BLRX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-55.536/58.39
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-55.536 / 19.2)*(19.2 / 58.39)
=Net Margin %*Asset Turnover
=-289.25 %*0.3288
=-95.11 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


BioLine Rx ROA % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023